JATT vs. LXEO, KYTX, ADPT, CABA, ALEC, VYGR, TCRX, OCGN, EDIT, and ALLO
Should you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include Lexeo Therapeutics (LXEO), Kyverna Therapeutics (KYTX), Adaptive Biotechnologies (ADPT), Cabaletta Bio (CABA), Alector (ALEC), Voyager Therapeutics (VYGR), TScan Therapeutics (TCRX), Ocugen (OCGN), Editas Medicine (EDIT), and Allogene Therapeutics (ALLO). These companies are all part of the "biological products, except diagnostic" industry.
JATT Acquisition (NYSE:JATT) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.
48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by insiders. Comparatively, 4.5% of Lexeo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
JATT Acquisition has higher earnings, but lower revenue than Lexeo Therapeutics.
In the previous week, Lexeo Therapeutics had 7 more articles in the media than JATT Acquisition. MarketBeat recorded 7 mentions for Lexeo Therapeutics and 0 mentions for JATT Acquisition. Lexeo Therapeutics' average media sentiment score of 1.05 beat JATT Acquisition's score of 0.00 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.
Lexeo Therapeutics received 6 more outperform votes than JATT Acquisition when rated by MarketBeat users.
JATT Acquisition's return on equity of -49.58% beat Lexeo Therapeutics' return on equity.
Lexeo Therapeutics has a consensus price target of $20.80, suggesting a potential upside of 25.08%. Given Lexeo Therapeutics' higher possible upside, analysts clearly believe Lexeo Therapeutics is more favorable than JATT Acquisition.
Summary
Lexeo Therapeutics beats JATT Acquisition on 7 of the 11 factors compared between the two stocks.
Get JATT Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
JATT Acquisition Competitors List
Related Companies and Tools
